The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Who is this study for? Patients with Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez
What treatments are being studied? Tranexamic Acid Tablets
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Subject age 18 and older

• Subject with a diagnosis of LPP, EDP, or AD

• Subject able to understand requirements of the study and risks involved

• Subject able to sign a consent form

• Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment

Locations
United States
Michigan
New Center One
RECRUITING
Detroit
Contact Information
Primary
Angela Parks-Miller, RN
amiller5@hfhs.org
1-313-916-0426
Backup
Jennifer Creasor, RN
jcreaso2@hfhs.org
1-313-916-0412
Time Frame
Start Date: 2020-03-17
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 5
Treatments
Experimental: Treatment
All five subjects will receive tranexamic acid tablets, 325mg twice daily for six months.
Related Therapeutic Areas
Sponsors
Leads: Henry Ford Health System

This content was sourced from clinicaltrials.gov